ArticleFrontiers in medicine2025
Global and regional burden of pneumoconiosis, 1990-2021: an analysis of data from the global burden of disease study 2021.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Global research landscape versus disease burden in pneumoconiosis diagnosis: a dual-source bibliometric analysis [1999-2025].Journal of thoracic disease · 2026Article
- Noninvasive early detection and grading of pneumoconiosis via plasma proteomics and machine learning: PRSS3 as a potential biomarker.Clinical proteomics · 2026Article
- Beyond Organ-Specific Therapies: A Unified Approach to Multi-Organ Fibrosis.Drug design, development and therapy · 2026Review
- Article
- Differential diagnosis of pneumoconiosis mass shadows and peripheral lung cancer using CT radiomics and the AdaBoost machine learning model.Frontiers in medicine · 2025Article
- Survival analysis of pneumoconiosis patients in Jiangsu Province from 1960 to 2024.Frontiers in public health · 2025Article
- Global, regional, and national trends in the incidence of pneumoconiosis among populations aged 20 and above from 1990 to 2021.Frontiers in public health · 2025Article
- Epidemiological analysis and temporal trends of interstitial lung diseases in global, Chinese, and Belt and Road Initiative countries: 1990-2021.Frontiers in medicine · 2025Article
- The disease burden of pneumoconiosis in China from 1990 to 2021 and projection to 2050 based on GBD 2021: a cross-sectional study.Frontiers in public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pneumoconiosis remains a widespread occupational disease globally. This study provides an updated overview of the global burden of pneumoconiosis, examining incidence and mortality from 1990 to 2021. Methods: The study assessed the incidence and mortality of pneumoconiosis using GBD data from 1990 to 2021, presenting findings as point estimates with 95% uncertainty intervals. Results: In 2021, there were 62,866 new pneumoconiosis cases and 18,323 deaths worldwide, with age-standardized incidence (ASIR) and age-standardized mortality rates (ASMR) of 0.736 and 0.219 per 100,000 population, respectively, showing decreases of 28.5 and 52.8% since 1990. The highest ASIR and ASMR of pneumoconiosis were found in middle and high-middle SDI quintiles in 2021, with East Asia having the highest ASIRs. ASIR and ASMR generally declined but rose in Australasia and Oceania from 1990 to 2021. Globally, the number of incidences peaked at 65-69 years in 1990 and 2021, with death peaks at 65-69 years in 1990 and 80-84 years in 2021. A correlation analysis revealed that ASIR and ASMR either decreased or remained stable in the majority of countries and territories as SDI increased. Decomposition analysis shows that population growth and aging drove the global number increase in most regions, while epidemiological changes had a negative impact. Conclusion: Despite an overall decline in global pneumoconiosis burden from 1990 to 2021, particularly in the middle and high-middle SDI quintiles, and in East Asia. The future looks promising, but pneumoconiosis remains a public health concern. The implementation of prevention strategies and improving the quality of life of current patients should be a priority.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.